When was Tessera Therapeutics founded?

Tessera Therapeutics was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Tessera Therapeutics located?

Tessera Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of Tessera Therapeutics?

Geoffrey Von Maltzahn of Tessera Therapeutics. They have also founded 3 companies.

How many employees does Tessera Therapeutics have?

As of Mar 31, 2026, the latest employee count at Tessera Therapeutics is 225.

Is Tessera Therapeutics a funded company?

Tessera Therapeutics is a funded company, having raised a total of $610M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Dec 20, 2017.

When was the latest funding round of Tessera Therapeutics?

Tessera Therapeutics' latest funding was a $***** Series C round on Apr 19, 2022, with participation from 10 investors.

Where does Tessera Therapeutics rank among its competitors?

Tessera Therapeutics ranks 4th amongst 874 active competitors, of which 149 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Precision BioSciences, which secured an undisclosed amount in Mar, 2026.

Who are the top competitors of Tessera Therapeutics?

Tessera Therapeutics' top competitors include eGenesis, Metagenomi and Mammoth. Among them, Precision BioSciences secured the most recent funding round in March, 2026.

Tessera Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Tessera Therapeutics is a provider of new genome engineering technology for treating multiple diseases. It offers a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. It offers RNA gene writings that can change base pairs, make small insertions or deletions, and integrate entire genes into the genome.

Website: tesseratherapeutics.com
Social
Email ID: *****@tesseratx.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Series C

Total Funding

$610M in 3 rounds

Latest Funding Round

Series C, Apr 19, 2022, $*****

Investors

Temasek & 23 more

Ranked

4^th among 874 active competitors

Employee Count

225 as on Mar 31, 2026

Similar Companies

eGenesis & 309 more

View Tessera Therapeutics' full profile

Tessera Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TESSERA THERAPEUTICS, INC CIN: 831788350 , United States, Active	Dec 31, 1999	-	308 (As on Dec 31, 2024)	-

Tessera Therapeutics has raised a total funding of $610M over 3 rounds. Its first funding round was on Dec 20, 2017. Its latest funding round was a Series C round on Apr 19, 2022 for $*****. 10 investors participated in its latest round. Tessera Therapeutics has 24 institutional investors.

Here is the list of recent funding rounds of Tessera Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 19, 2022	8917911	Series C	6495246	4219985	8655337	8355042
Jan 12, 2021	2780021	Series B	7862946	9691686	2967984	Qatar Investment Authority
Dec 20, 2017	7049706	Series B	8448419	9812637	Temasek	EDBI & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Tessera Therapeutics's funding rounds and investors

The founders of Tessera Therapeutics are Geoffrey Von Maltzahn and Robert Citorik.

Here are the details of Tessera Therapeutics' key team members:

Geoffrey Von Maltzahn: Co-Founder & CEO of Tessera Therapeutics and founder of 6 other companies, including Quotient, Indigo and Sana Biotechnology.
Contact Info: 1 email address
Robert Citorik: Co-Founder & Director of Tessera Therapeutics.

View details of Tessera Therapeutics's Founder profiles and Board Members

Tessera Therapeutics' employee count trend

Tessera Therapeutics has 225 employees as of Mar 26. Here is Tessera Therapeutics's employee count trend over the years:

Employee count trend for Tessera Therapeutics

Uncover Tessera Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tessera Therapeutics include eGenesis, Metagenomi and Mammoth. Here is the list of Top 10 competitors of Tessera Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$481M	Monashee Investment Management, Biomatics Capital ... & 30 others	66/100
2nd	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Mayfield & 34 others	65/100
4th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	ADIA, Temasek & 22 others	64/100
5th	Strand Life Sciences 2000, Bengaluru (India), Acquired	Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery	$34.9M	Biomark Capital, Quadria Capital & 92 others	64/100
6th	Precision BioSciences 2006, Durham (United States), Public	Developer of gene editing therapies to treat rare genetic diseases	$136M	ArrowMark Partners, VenBio & 29 others	64/100
7th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	The Column Group, 8VC & 10 others	63/100
8th	Scribe Therapeutics 2018, Alameda (United States), Series B	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 6 others	61/100
9th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	61/100
10th	ONCOHOST 2017, Binyamina Giv at Ada (Israel), Series C	AI-based oncology therapy plan solution for professionals	$43M	OurCrowd, ALIVE & 5 others	61/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Tessera Therapeutics's competitors? Click here to see the top ones

Tessera Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Tessera Therapeutics's sector:

Free

Internet of Things - Sector Report

Edition: March, 2026 (83 Pages)

View all reports related to Tessera Therapeutics

Media has covered Tessera Therapeutics for a total of 6 events in the last 1 year, 3 of them have been about company updates and 2 about partnerships.